China 130309-37-4 Fmoc-L-Oic-OH Manufacturer and Factory

130309-37-4 Fmoc-L-Oic-OH

Short Description:

Appearance	white powder
MF	C24H25NO4
MW	391.46
Purity	98+

Send email to us

Product Detail

Transportation condition
Could be in normal temperature

Recommend shipping method
By air By land By sea

Storage condition:
Keep in dark place,Inert atmosphere,Room temperature

shelf life
About 2 years

Minimum Order Qty：
1kg （negotiation）

Certification: COA, melting point, SpecificRotation [α]_D²⁰

We will send any data you want. You can see the data before as reference.

For customized products, we send the newest data after they come out.

Synonyms

Fmoc-L-octahydroindole-2-carboxylicacid

FMOC-OIC-OH;

FMOC-L-OIC-OH;

FMOC-L-OCTAHYDROINDOLE-2-CARBOXYLICACID;

(S)-N-(9-Fluorenylmethyloxycarbonyl)-octahydroindolecarboxylicacid,(2S,3aS,7aS)-1-(9-Fluorenylmethyloxycarbonyl)-octahydro-1H-indole-L-2-carboxylicacid;

(2S,3AS,7AS)-1-FMOC-OCTAHYDRO-1H-INDOLE-2-CARBOXYLICACID;

(2S,3AS,7AS)-FMOC-1-OCTAHYDRO-1H-INDOLE-2-CARBOXYLICACID;

(S)-N-(9-FLUORENYLMETHYLOXYCARBONYL)-OCTAHYDROINDOLECARBOXYLICACID

inner Packing

They are often used for packing powder. It depends on customers` requirement. Therefore, tell us your demanding before packing if you have special requests.

outer packing

1kg to 25kg The outer packing is hard. And it is difficult to cut and damage. It can protect your products perfectly.

Applications

130309-37-4 Fmoc-L-Oic-OH could be one of intermediates of Icatibant. Icatibant is a selective competitive antagonist of bradykinin B2 receptor with affinity similar to bradykinin. Hereditary angioedema (HAE) is caused by the deficiency or dysfunction of C1-esterase inhibitor. Bradykinin, a vasodilator, is considered responsible for the localized swelling, inflammation, and pain that are characteristic symptoms of HAE. Icatibant treats the acute clinical symptoms of HAE by inhibiting the binding of bradykinin to B2 receptor. Besides, it also has potential indications for the treatment of asthma, liver cirrhosis, and other types of angioedema.

130309-37-4 Fmoc-L-Oic-OH also could be one of intermediates of Relugolix. Relugolix, a new drug jointly developed by Myovant and Takeda Pharmaceutical, is a small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist with potential indications for uterine fibroids, endometriosis, prostate cancer, and other conditions.

Why Choose Us

1. About the MOQ: We can adjust it according to your requirement.
2. About the sample: The sample requires the sample fee, which can be freight to collect or you can pay to us in advance.
3. Mold workshop, can be customized according to the number of models.
4. We provide the best service. An experienced sales team is already working for you.
5. About the exchange: Please email or chat me at your convenience.

Previous: 130309-33-0 Fmoc-D-Tic-OH

Next: 162537-11-3 Moc-L-tle

130309-37-4